CureVac NV reports Q3 net profit of €273.2 million and nine-month net profit of €161.6 million
CureVac NV reported a net profit of €273.2 million for the third quarter of 2025, down from €338.0 million in the same period of 2024. Net profit for the first nine months of 2025 was €161.6 million, compared to €194.9 million in the prior-year period. The net financial result showed a loss of €2.6 million for the third quarter of 2025, compared to a gain of €2.2 million in the previous year, mainly due to unrealized foreign exchange losses. Basic and diluted earnings per share for the third quarter were €1.21, compared to €1.51 and €1.50 respectively in 2024. For the first nine months, basic earnings per share were €0.72 and diluted earnings per share were €0.71, down from €0.87 and €0.86 in the previous year. Revenues were €54.1 million for the third quarter and €56.3 million for the first nine months of 2025. Business developments included clearance from the German Federal Cartel Office for the planned BioNTech-CureVac transaction and the start of BioNTech's public exchange offer for all outstanding CureVac shares, set to expire on December 3, 2025. CureVac also reaffirmed its expected cash runway into 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureVac NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2235000_en), on November 24, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.